[1] 中华医学会呼吸病学分会哮喘学组.奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J].中华结核和呼吸杂志,2022,45(4):341-354. [2] AGACHE I,BELTRAN J,AKDIS C,et al.Efficacy and safety of treatment with biologicals(benralizumab,dupilumab,mepolizumab,omalizumab and reslizumab)for severe eosinophilic asthma:A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma[J].Allergy,2020,75(5):1023-1042. [3] 陈玉迪,胡艳,隋海晶,等.抗IgE单克隆抗体在变态反应性疾病治疗中的应用[J].中华临床免疫和变态反应杂志,2018,12(3):302-307. [4] 奥马珠单抗治疗过敏性哮喘专家组,中华医学会呼吸病学分会哮喘学组.奥马珠单抗治疗过敏性哮喘的中国专家共识[J].中华结核和呼吸杂志,2018,41(3):179-185. [5] VOGEL U,van STEKELENBORG J,DREYFUS B,et al.Investigating overlap in signals from EVDAS,FAERS,and VigiBase®[J].Drug Saf,2020,43(4):351-362. [6] MOORE T J,MORROW R L,DORMUTH C R,et al.US food and drug administration safety advisories and reporting to the adverse event reporting system(FAERS)[J].Pharmaceut Med,2020,34(2):135-140. [7] 董士超,霍小东,孙川,等.基于真实世界监测数据挖掘与分析奥希替尼上市后的不良反应信号[J].中国医院药学杂志,2022,42(6):642-646. [8] 陈耀鑫,伍绍星,李浩轩,等.美泊利单抗相关不良事件信号的挖掘与分析[J].中国药房,2023,34(11):1374-1378. [9] U.S.FDA.FDA Adverse Event Reporting System(FAERS)quarterly data extract files[EB/OL].[2023-08-05].https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. [10] 罗宝章,钱轶峰,叶小飞,等.药物不良反应信号检测方法的现状与展望[J].药学服务与研究,2009,9(4):255-260. [11] NORÉN G N,BATE A,ORRE R,et al.Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events[J].Stat Med,2006,25(21):3740-3757. [12] GUAN Y Y,JI L,ZHENG L,et al.Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions[J].Front Pharmacol,2022(13):892503. [13] 陈雪琴,贾心予,吴晶晶,等.奥马珠单抗治疗难治性过敏性哮喘疗效和安全性的荟萃分析[J].中华医学杂志,2022,102(28):2201-2209. [14] 张红盼,孙燕燕,田丹丽.奥马珠单抗不良反应文献分析[J].中国医院药学杂志,2022,42(18):1939-1942. [15] XIE M,LIU X,CAO X,et al.Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017[J].Respir Res,2020,21(1):49. [16] 陈广道,刘运可,王亚曙,等.喀什地区和广州地区过敏性疾病儿童过敏原IgE阳性率比较[J].广州医药,2021,52(4):123-126. [17] BIAN S,ZHANG P,LI L,et al.Anaphylaxis associated with allergen specific immunotherapy,omalizumab,and dupilumab:A real world study based on the US food and drug administration adverse event reporting system[J].Front Pharmacol,2021(12):767999. [18] LI L,WANG Z,CUI L,et al.Anaphylactic risk related to omalizumab,benralizumab,reslizumab,mepolizumab,and dupilumab[J].Clin Transl Allergy,2021,11(4):e12038. [19] 屠莹,马晖,陈丽娟,等.基于FAERS数据库儿童应用奥马珠单抗安全信号挖掘与分析[J].中国医院药学杂志,2023,43(1):87-91. [20] 广东省老年保健协会呼吸科专业委员会.老年患者新型冠状病毒感染诊疗与康复专家共识[J].广州医药,2023,54(3):14-20,47. [21] VAHLE J L.Immunogenicity and immune complex disease in preclinical safety studies[J].Toxicol Pathol,2018,46(8):1013-1019. [22] PERA V,BRUSSELLE G G,RIEMANN S,et al.Parasitic infections related to anti-type 2 immunity monoclonal antibodies:A disproportionality analysis in the food and drug administration’s adverse event reporting system(FAERS)[J].Front Pharmacol,2023(14):1276340. [23] AGACHE I,AKDIS C A,AKDIS M,et al.EAACI Biologicals Guidelines-Recommendations for severe asthma[J].Allergy,2021,76(1):14-44. [24] GE W,GUO X,SONG X,et al.The role of immunoglobulin E and mast cells in hypertension[J].Cardiovasc Res,2022,118(14):2985-2999. [25] IRIBARREN C,RAHMAOUI A,LONG A A,et al.Cardiovascular and cerebrovascular events among patients receiving omalizumab:Results from EXCELS,a prospective cohort study in moderate to severe asthma[J].J Allergy Clin Immunol,2017,139(5):1489-1495.e5. |